Full Pivalate educator webinar and pipeline. Worth the watch. Riccardo presents it exceptionally once again.
A slide from the webinar with catalysts this year.
We have seen Paul Hopper recently execute a $10.1 million investment in his other company CHM by a US institutional investor, Lind via a Placement
Agreement. RAD being later stage and the success of the phase 2 trails for Pivalate IMO RAD will have no trouble attracting a similar not dilutive raise over here (when they need it) Cash runway till end of 2023. They have stated their listing on Nasdaq will attract more opportunities for biotech funds who get the science and the value and the opportunity.
Block out the noise, good opportunity to get some lower here while they finalise Nasdaq listing and get the Phase 2/3 underway.
RAD is a Phase 2/3 stage Biotech at $30m MC with excellent data. Those with patience will be rewarded.
Full Pivalate educator webinar and pipeline. Worth the watch....
-
- There are more pages in this discussion • 125 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.0¢ |
Change
-0.002(6.25%) |
Mkt cap ! $31.72M | |||
| Open | High | Low | Value | Volume |
| 3.4¢ | 3.4¢ | 3.0¢ | $148.0K | 4.757M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1108739 | 3.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.1¢ | 391603 | 5 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| RAD (ASX) Chart |